Product Description
Mechanisms of Action: VEGFR2 Inhibitor,AhR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Colorectal Cancer
Phase 2: Skin Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Melanoma|Plasmacytoma|Multiple Myeloma|Kidney Cancer|Renal Cell Carcinoma|Gastrointestinal Stromal Tumors|Mesothelioma|Sarcoma|Prostate Cancer|Colorectal Cancer|Uterine Cancer|Cervical Cancer|Astrocytoma|Adenocarcinoma|Glioma|Brain Stem Cancer|Sarcoma, Kaposi|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Preleukemia|Chronic Myeloid Leukemia|Acute Myelomonocytic Leukemia|HIV Infections|Chronic Myelomonocytic Leukemia|Acute Myeloid Leukemia|Anemia, Aplastic
Phase 1: Oncology Solid Tumor Unspecified|Brain Stem Cancer|Sarcoma, Kaposi|Head and Neck Cancer|Vascular Cancer|Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer|Inflammatory Breast Cancer|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SUGEN-SU5416.031 | P3 |
Completed |
Colorectal Cancer |
2007-09-01 |
|
| U01CA062505 | P2 |
Completed |
Kidney Cancer|Renal Cell Carcinoma |
2007-02-01 |
|
| NCI-2012-02345 | P2 |
Terminated |
Colorectal Cancer |
2007-02-01 |
|
| NCI-2012-02351 | P2 |
Completed |
Mesothelioma |
2007-02-01 |